MedPath

Levothyroxine

Generic Name
Levothyroxine
Brand Names
Eltroxin, Ermeza, Euthyrox, Levo-T, Levothroid, Levoxyl, Np Thyroid, Synthroid, Thyquidity, Tirosint, Unithroid
Drug Type
Small Molecule
Chemical Formula
C15H11I4NO4
CAS Number
51-48-9
Unique Ingredient Identifier
Q51BO43MG4
Background

Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T (tetraiodothyronine or thyroxine) and T (triiodothyronine or Liothyronine), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.

In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T. While T is the major product secreted by the thyroid gland, T exerts the majority of the physiological effects of the thyroid hormones; T and T have a relative potency of ~1:4 (T4:T3). T and T act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status.

Prior to the development of levothyroxine, Thyroid, porcine or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.

Indication

Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Associated Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite), Hypothyroidism, Localized Adiposity, Myxedema coma, Euthyroid Goitre, Thyrotropin dependent Well-Differentiated Thyroid Cancer
Associated Therapies
-

The TRUST Trial - CardioVascular Imaging ECHO

Phase 4
Completed
Conditions
Atherosclerosis
Thyroid Dysfunction
Heart Failure
Interventions
Drug: Placebo
Drug: Levothyroxine
First Posted Date
2016-07-14
Last Posted Date
2017-02-28
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
185
Registration Number
NCT02832960
Locations
🇨🇭

Clinic for General Internal Medicine, Bern University Hospital Bern, Bern, Switzerland

🇨🇭

Cardiology Division, Geneva University Hospitals, Geneva, Switzerland

🇨🇭

Department of General Internal Medicine, Lausanne, Vaud, Switzerland

Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding

Phase 4
Withdrawn
Conditions
Hypothyroidism
Interventions
First Posted Date
2015-10-16
Last Posted Date
2021-09-22
Lead Sponsor
Jocelyne Karam
Registration Number
NCT02577367
Locations
🇺🇸

Maimonides Medical Center, Brooklyn, New York, United States

Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?

Terminated
Conditions
Hypothyroidism
Postsurgical Hypothyroidism
Interventions
First Posted Date
2015-10-05
Last Posted Date
2023-06-08
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
12
Registration Number
NCT02567877
Locations
🇺🇸

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Levothyroxine Treatment for Subclinical Hypothyroidism After Head and Neck Surgery

Phase 2
Withdrawn
Conditions
Hypothyroidism
Neoplasms
Postoperative Complications
Interventions
Drug: Placebo
Drug: Levothyroxine
First Posted Date
2015-09-14
Last Posted Date
2022-07-13
Lead Sponsor
University of Alberta
Registration Number
NCT02548715

Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction(ThyroHeart-AMI)

Phase 4
Conditions
Myocardial Infarction
Hypothyroidism
Interventions
First Posted Date
2015-07-31
Last Posted Date
2018-07-16
Lead Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Target Recruit Count
160
Registration Number
NCT02512978
Locations
🇨🇳

Fuwai Cardiovascular Hospital, Beijing, China

The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus.

Not Applicable
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Placebo
Drug: thyroxine
Other: A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)
First Posted Date
2015-07-28
Last Posted Date
2015-07-28
Lead Sponsor
Attikon Hospital
Target Recruit Count
33
Registration Number
NCT02509858

Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism

Phase 4
Completed
Conditions
Thyroid Dysfunction
Mental Fatigue
Fatigue
Interventions
Drug: Placebo
Drug: Levothyroxine
First Posted Date
2015-07-16
Last Posted Date
2019-03-29
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
276
Registration Number
NCT02500342
Locations
🇮🇪

University College Cork, National University of Ireland, Cork, Ireland

🇨🇭

Clinic for General Internal Medicine, Bern University Hospital Bern, Bern, Switzerland

🇨🇭

Department of General Internal Medicine, Lausanne, Vaud, Switzerland

Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction

Phase 4
Completed
Conditions
Thyroid Dysfunction
Bone Mineral Density
Osteoporosis
Fractures, Bone
Interventions
Drug: Levothyroxine
Drug: Placebo
First Posted Date
2015-07-07
Last Posted Date
2017-02-01
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
145
Registration Number
NCT02491008
Locations
🇨🇭

Clinic for General Internal Medicine, Bern University Hospital Bern, Bern, Switzerland

🇨🇭

Department of General Internal Medicine, Lausanne, Vaud, Switzerland

Effect of Levothyroxine on Serum Adiponectin, Insulin Resistance and Cardiovascular Risk in Patients With Hypothyroidism

Completed
Conditions
Hypothyroidism
Interventions
First Posted Date
2015-06-10
Last Posted Date
2019-10-01
Lead Sponsor
All India Institute of Medical Sciences, Bhubaneswar
Target Recruit Count
120
Registration Number
NCT02467244
Locations
🇮🇳

AIIMS, Bhubaneswar, Bhubaneshwar, Odisha, India

Mechanistic Study of Subclinical Hypothyroidism In the Elderly

Not Applicable
Completed
Conditions
Subclinical Hypothyroidism
Interventions
Drug: Levothyroxine
Drug: Liothyronine
Drug: Thyrotropin-Releasing Hormone
First Posted Date
2015-03-26
Last Posted Date
2021-03-09
Lead Sponsor
University of Pennsylvania
Target Recruit Count
14
Registration Number
NCT02399475
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath